Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novan Inc (NOVN)

Novan Inc (NOVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,437
  • Shares Outstanding, K 26,715
  • Annual Sales, $ 5,990 K
  • Annual Income, $ -12,670 K
  • 60-Month Beta 1.84
  • Price/Sales 9.50
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.45
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -192.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.82 +18.20%
on 11/19/19
2.42 -11.26%
on 11/08/19
unch (unch)
since 11/06/19
3-Month
1.82 +18.20%
on 11/19/19
3.01 -28.57%
on 09/11/19
-0.47 (-17.94%)
since 09/06/19
52-Week
0.65 +230.77%
on 04/17/19
3.02 -28.81%
on 06/10/19
+0.83 (+62.26%)
since 12/06/18

Most Recent Stories

More News
U.S. FDA Approves SECUADO(R) (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO (R) (asenapine) transdermal...

HTSUF : 38.5000 (-6.33%)
NOVN : 2.15 (+0.94%)
Acne Vulgaris Treatment Market Expand Steadily Potential Growth and Analysis, 2018-2026

Acne vulgaris is a common skin disease characterized by blackheads, whiteheads, papules, and pustules on the face, neck, back, and chest. Although the condition is more prevalent in adolescent population,...

AGN : 186.37 (+0.16%)
BAYRY : 19.1200 (-0.26%)
GSK : 45.51 (+0.66%)
NOVN : 2.15 (+0.94%)
PFE : 38.29 (+0.68%)
VRX.TO : 30.80 (-3.33%)
Novan's Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum...

NOVN : 2.15 (+0.94%)
Noven Announces Appointment of Dr. Naruhito Higo as Chief Executive Officer

Noven Pharmaceuticals, Inc. today announced its decision to appoint Dr. Naruhito Higo as Chief Executive Officer effective October 1, 2019, succeeding Jeff Mihm who has tendered his resignation. Noven...

HTSUF : 38.5000 (-6.33%)
NOVN : 2.15 (+0.94%)
Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Compensation Committee of Novan's Board of Directors granted stock options to purchase an aggregate of 25,000 shares of its...

NOVN : 2.15 (+0.94%)
Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the "Agreement") of up to $25 million with Aspire Capital Fund,...

NOVN : 2.15 (+0.94%)
Novan Hires Michelle Patterson as Vice President of Project Management

-- Underscores Company's preparation for potential NDA submission for SB206 in molluscum

NOVN : 2.15 (+0.94%)
Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York on Monday, September 9, 2019. Participation...

NOVN : 2.15 (+0.94%)
Iconic Therapeutics Signs Ophthalmology Option Agreement

Iconic Therapeutics, a private biopharmaceutical company focused on novel therapeutics for serious diseases such as cancer and age-related macular degeneration (AMD), today announced that the Company has...

NVS : 92.07 (+0.47%)
NOVN : 2.15 (+0.94%)
Novan Takes Steps to Reduce Real Estate Footprint

Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has executed a non-binding letter of intent (LOI) with a third party on its facility at 4105 Hopson Road in Morrisville,...

NOVN : 2.15 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade NOVN with:

Business Summary

Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through...

See More

Key Turning Points

2nd Resistance Point 2.24
1st Resistance Point 2.19
Last Price 2.15
1st Support Level 2.11
2nd Support Level 2.08

See More

52-Week High 3.02
Last Price 2.15
Fibonacci 61.8% 2.11
Fibonacci 50% 1.84
Fibonacci 38.2% 1.56
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar